News
10-11-2011, 05:10 AM
BioSante Pharmaceuticals, Inc., announced today that the independent Data Monitoring Committee (DMC) has completed the seventh unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects.
More... (http://www.news-medical.net/news/20111011/DMC-completes-review-of-BioSantes-LibiGel-Phase-III-cardiovascular-and-breast-cancer-study.aspx)
More... (http://www.news-medical.net/news/20111011/DMC-completes-review-of-BioSantes-LibiGel-Phase-III-cardiovascular-and-breast-cancer-study.aspx)